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ABSTRACT
Identifying founder mutations in BRCA1 and BRCA2 in specific populations 
constitute a valuable opportunity for genetic screening. Several studies from different 
populations have reported recurrent and/or founder mutations representing a 
relevant proportion of BRCA mutation carriers. In Latin America, only few founder 
mutations have been described. We screened 453 Chilean patients with hereditary 
breast cancer for mutations in BRCA1 and BRCA2. For recurrent mutations, we 
genotyped 11 microsatellite markers in BRCA1 and BRCA2 in order to determine a 
founder effect through haplotype analysis. We found a total of 25 mutations (6 novel) 
in 71 index patients among which, nine are present exclusively in Chilean patients. 
Our analysis revealed the presence of nine founder mutations, 4 in BRCA1 and 
5 in BRCA2, shared by 2 to 10 unrelated families and spread in different regions of 
Chile. Our panel contains the highest amount of founder mutations until today and 
represents the highest percentage (78%) of BRCA1 and BRCA2 mutation carriers. We 
suggest that the dramatic reduction of Amerindian population due to smallpox and 
wars with Spanish conquerors, a scarce population increase during 300 years, and 
the geographic position of Chile constituted a favorable scenario to establish founder 
genetic markers in our population.
INTRODUCTION
It is well known that an early detection of breast 
cancer is highly relevant in relation to patient survival, 
for this reason a genetic analysis revealing a high risk 
to breast cancer for healthy women constitutes valuable 
information. Twenty years ago two genes, BRCA1 (MIM: 
113705) and BRCA2 (MIM: 600185), which mutations 
confer a high risk to breast cancer were identified in 
families having four or more relatives with breast or 
ovarian cancer [1, 2]. Since then, the screening of BRCA1 
and BRCA2 has been performed in multiple populations 
across the world revealing that 10 to 50% of breast cancer 
patients with family history of breast and/or ovarian 
cancer carry a BRCA1 or BRCA2 mutation [3]. In Chile, 
we and others have carried out mutation screening of 
BRCA1 and BRCA2 in hereditary breast cancer patients, 
leading into mutation frequencies ranging from 15% 
[4] to 20% [5].  Among Latin American countries, eight 
similar studies have been published up today: México [6], 
Colombia [7], Brazil [8], Argentina [9], Uruguay [10], 
Venezuela [11] and Chile [4, 5]. Among those studies the 
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frequency of mutation carriers in Latin American women 
with hereditary breast cancer varies from 15% to 25%.
The presence of founder mutations in BRCA1 and 
BRCA2 in specific ethnic groups or populations constitutes 
a valuable opportunity for a genetic screening. The most 
well-known example is the Ashkenazi Jewish population 
[12], in which three founder mutations combined have 
a population frequency of 2% and represent 60% of 
breast cancer families with a BRCA gene mutation. A 
second well-known example is the Icelandic population 
in which one founder mutation in BRCA2 999del5 has a 
population carrier frequency of 0.4%, and account for 64% 
of breast cancer families [13, 14, 15]. In the last 15 years 
several studies have described recurrent mutations in 
breast cancer patients, some of which have documented 
a single origin (founder effect) of such recurrent mutation 
through haplotype analyses. In this relation, it is necessary 
to highlight that a recurrent mutation is not necessary 
founder, since some recurrent mutations may correspond 
to hotspots, arising independently in a population. To be 
founder, a minimum common haplotype must be identified 
among carriers of a certain recurrent mutation. In Poland 
[16] three founder mutations account for up to 86% of all 
families with a BRCA1 or BRCA2 mutation. In Slovenia 
five founder mutations account for 69% of all BRCA 
families [17]. Several other studies from Europe, Asia and 
North America have reported recurrent and/or founder 
mutations that represent a relevant proportion of BRCA1 
and BRCA2 mutation carriers [18]. In Latin America, there 
are few different mutations with a demonstrated founder 
effect described in different populations: Mexico (BRCA1 
ex9–12del), Brazil (BRCA1 5382insC), Colombia (BRCA1 
3450del4, A1708E, and BRCA2 3034del4) and US 
Hispanics (BRCA1 185delAG, IVS5+1G>A, S955X, and 
R1443X) [19, 20]. In addition to these founder mutations, 
other recurrent mutations have been described in Latin 
American populations which founder effect through 
haplotype analyses still has not been tested.
In Chile, our group has screened BRCA1 and BRCA2 
genes in 336 patients with a family history of breast cancer 
and 117 patients unselected for family history, recruited 
throughout the country. The results of this study led us 
to define a panel of 9 founder mutations among Chilean 
patients representing 77.5% of total BRCA mutation carriers. 
RESULTS 
Novel and recurrent mutations in BRCA1 and 
BRCA2
We identified 25 different mutations (pathogenic 
variants, class 5), of which 6 are novel and 19 have 
been previously reported (Table 1). These mutations 
are present in 71 index patients, of which 32 carried a 
mutation in BRCA1 (7.06%) and 39 (8.61%) in BRCA2 
leading to a combined mutation prevalence of 15.7% 
(71/453). It is noteworthy that considering only cases 
with family history this percentage is higher, being 17.9 
%. Nine of the 25 mutations described in this work have 
been found exclusively in Chilean patients [4, 5, 21] (and 
this study), two of them being recurrent in our samples 
(c.1504_1507delTTAA and c.3817C>T, both in BRCA1) 
(Table 1). We have to remark that mutation p.Asp2723Gly 
has been previously described (BIC) as a variant of 
uncertain significance in several populations and in 2008, 
a functional analysis made by Farrugia et al. [22] defined 
that this aminoacid change was detrimental for BRCA2 
function in DNA repair and centrosome duplication. 
Since then this mutation has been defined as pathogenic. 
Mutation c.211A>G in BRCA1 (previously named as 
R71G) is located in the before last nucleotide of exon 5, 
eliminating the donor splice site in this exon and revealing 
a cryptic splice site 22 nucleotides upstream. The deletion 
of 22 nucleotides in the mRNA creates a stop codon in 
position 64 [23]. We corrected the protein nomination for 
this mutation from the previous p.Arg71Gly to p.Cys64Ter. 
Considering all mutations (n = 25) 9 were recurrent 
in our sample set (Table 1, highlighted in bold). This group 
of nine mutations is present in 77.5% (55/71) of total BRCA 
carriers, becoming an excellent panel for cost-effective 
BRCA1 and BRCA2 mutational screening in Chilean 
patients. The most frequent of these nine recurrent mutation 
is c.4740_4741dupTG in BRCA2 (Table 1).  This mutation 
was first described in Chilean patients by our group [5] 
and later found by two groups in unrelated Chilean [21], 
and Argentinian patients [24]. Two other frequent recurrent 
mutations (BRCA1 c.3331_3334delCAAG and BRCA2 
c.5146_5149delTATG) were found in 9 families each. 
Common haplotypes found for recurrent BRCA1 
and BRCA2 mutations 
In order to determine a probable founder effect for 
the 9 recurrent mutations we analyzed 11 STR markers 
(6 for BRCA1 and 5 for BRCA2) in 53 index patients and 
established the corresponding haplotypes. Patients sharing 
the same mutation belong to apparently unrelated families 
residing in different regions along Chile as it is shown in 
Figure 1. 
All microsatellites for BRCA1 and BRCA2 were 
informative (Figure 2). For three mutations in BRCA1, 
c.1504_1507delTTAA (2 families), c.3331_3334delCAAG 
(9 families) and c.3817C>T (4 families), the core 
haplotype (identical haplotype at loci) was shaped with 
the six microsatellites markers (Figure 2A) revealing 
no recombinants in a region of 0.68 Mb. For the fourth 
mutation, c.3759dupT, the core haplotype was shaped with 
four markers (Figure 2A) covering a region of 0.46 Mb. 
In this case one sample is a recombinant for D17S1326 
and two samples for markers D17S1327 and D17S1326. 
On the other hand, for three mutations in BRCA2, 
c.145G>T (3 families), c.4740_4741dupTG (6 families) 
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and c.8987T>A (6 families), the core haplotype was 
shaped with the five microsatellites markers (D13S260, 
D13S1698, D13S171, D13S310 and D13S267) revealing 
no recombinants in a region of 1.82 Mb (Figure 2B). 
Conversely, for mutations c.5146_5149delTATG 
(8 families) and c.9382T>A (3 families) we found one 
recombinant for D13S260 in our samples. For both 
mutations the minimum common haplotype covers 
1.56Mb (Figure 2B). We were able to determine a common 
haplotype for all the analyzed mutations. 
Polymorphisms and unclassified variants in 
BRCA1 and BRCA2
We found a total of 110 coding and non-coding 
variants, 15 not previously reported in the literature or 
public data bases. Among the 95 reported variants, 62 
correspond to polymorphisms (allelic frequencies ≥ 1%, 
not pathogenic, class 1) reported in at least one population 
in the 1000 Genomes database. In addition we detected 
33 rare variants (Supplementary Table 1), either with 
allelic frequencies < 1% in all populations reported (1000 
Genomes or dbSNP) or allelic frequencies not reported. 
The classification of the 33 rare variants (Supplementary 
Table 1) was concluded after revising three databases 
(BIC, ClinVar, BRCA Share) and functional assays in 
published papers. Nineteen of these variants have been 
classified as “benign” or “likely benign” (also neutral/
likely neutral) in ClinVar and BRCA Share databases 
(Supplementary Table 1). Seven variants are reported 
as “unclassified variant” or “variant with uncertain 
significance” (Supplementary Table 1: ClinVar, BRCA 
Share). The remaining 7 variants have a controversial 
classification, being reported as benign/likely benign 
(neutral/likely neutral) by one database and uncertain 
by another. Among the 14 variants reported previously, 
at least once in data bases as “uncertain”, three have 
been tested in functional assays concluding a neutral 
or non-pathogenic effect, indicated under conclusion 
in Supplementary Table 1. In summary, according to 
ENIGMA recommendations and considering reported 
in silico analyses, functional assays, and co-occurrence 
with a BRCA1/2 pathogenic variant, there are 17 not 
pathogenic and 6 likely not pathogenic variants. For 10 
rare variants there was insufficient information so were 
interpreted as “uncertain” (Supplementary Table 1).
In relation to novel variants in this study a total of 
11 are described in Table 2. Among these, 6 are coding 
variants and 5 non-coding. In the coding region only 
two novel synonymous variants were found in our study. 
Table 1: Mutations in BRCA1 and BRCA2 in Chilean breast cancer patients
Gene Number of families Exon
Systematic nomenclature (HGVS) Previously named as
Population(s) Reported
cDNA Protein cDNA Protein
BRCA1 1 2 c.68_69delAG p.Glu23Valfs*17 185delAG Stop 39 Ashkenazi-Jewish
1 5 c.181T>G p.Cys61Gly 300T>G C61G Europe
1 5 c.187_188insA p.Leu63Tyrfs*3 308insA Stop 65 Chile1
1 5 c.211A>G p.Cys64Ter 330A>G R71G Global
1 7 c.303T>A p.Tyr101Ter - - NO 
2 11 c.1504_1507delTTAA p.Leu502Serfs*29 - - NO 
1 11 c.2486_2487delTT p.Phe829Ter 2605_2606delTT F829X Chile2
9 11 c.3331_3334delCAAG p.Gln1111Asnfs*5 3450del4 Stop1115 Global
7 11 c.3759dupT p.Lys1254Ter 3878insT Stop 1254 Global
4 11 c.3817C>T p.Gln1273Ter 3936C>T Q1273X Chile1
1 11 c.3858_3861delTGAG p.Ser1286Argfs*20 3977del4 Stop 1305 China, Chile2
1 11 c.3968_3971delAAAT p. Gln1323Argfs*11 - - NO
1 11 c.4065_4068delTCAA p. Asn1355Lysfs*10 4184del4 Stop 1364 Global
1 20 c.5266dupC p.Gln1756Profs*74 5382insC Stop 1829 Ashkenazi-Jewish
BRCA2 5 3 c.145G>T p.Glu49Ter 373G>T E49X Globally
10 11 c.4740_4742dupTG p.Glu1581Valfs*37 4970insTG Stop 1617 Chile1,2 Argentina3
9 11 c.5146_5149delTATG p.Tyr1716Lysfs*8 5373delGTAT Stop 1724 Spain and Chile1,2
1 11 c.5946delT p.Ser1982Argfs*22 6174delT Stop 2003 Ashkenazi-Jewish
1 11 c.6629_6630delAA p.Glu2210Glyfs*14 6857delAA Stop 2223 Spain and Chile1
1 14 c.7397dupC p.Ala2466Alafs*8 - - NO
1 18 c.8168A>G p.Asp2723Gly 8396A>G D2723G Global
1 18 c.8223_8224dup11 p.Asn2742Leufs* - - NO
1 22 c.8941G>T p.Glu2981Ter - - NO
6 23 c.8987T>A p.Leu2996Ter - - Once in ClinVar origin not provided
3 25 c.9382C>T p.Arg3128Ter 9610C>T R3128X Global
1Gallardo et al. 2006, 2González-Hormazabal et al. 2011, 3Solano et al., 2016. NO: not reported previously, first mentioned in this manuscript. GeneBank 
Accession Numbers: BRCA1: L78833 and BRCA2: AY436640.
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These variants are predicted to produce a weak or null 
effect in splicing by the three utilized tools. On the other 
hand among these, 2 variants, p.Pro34 = co-occur with 
a mutation in BRCA1, c. 211A>G. These results suggest 
that these variants should be classified as neutral or non-
pathogenic. 
Three variants are novel non-synonymous (Table 2), 
and none of them co-occur with a BRCA mutation. 
Determining the functional effect of a missense variant is 
a relevant step to interpret their possible pathogenic role 
in breast cancer. The analysis tools give contradictory 
predictions for 2/3 variants, so these should be classified 
as uncertain, until a functional effect can be assessed. 
Variants c.4746C>G has a null effect predicted by all tools. 
Finally, we found one novel truncating variant in 
exon 27 of BRCA2 (Table 2: p.Gln3409Ter) downstream 
of p.Lys3326Ter, which is frequently described as neutral 
(ClinVar). For this reason we assumed that the new variant 
should also be neutral as recommended by ENIGMA. Non-
coding novel variants are deep in the introns and according 
to ENIGMA recommendations and ACMG guidelines they 
should be considered as non-pathogenic. None of these 
novel variants co-occur with a pathogenic mutation. 
DISCUSSION
We described the screening of BRCA1 and BRCA2 
in a Chilean cohort of 453 patients.  As shown in Table 3 
the higher percentage of patients with a mutation in 
BRCA1/2 is among families with a male breast cancer 
(40%, only in BRCA2), followed by the group having 
breast and ovarian cancer cases (37.7%) being higher 
for BRCA1. In relation to patients with no family history 
the highest percentage of mutation carriers is among 
bilateral breast cancer patients. It is noteworthy that in 
the group of younger patients < 40 y 6/7 patients have a 
mutation in BRCA1. In summary the distribution of BRCA 
mutation carriers is not remarkably different to what has 
been already described in other breast cancer cohorts. In 
relation to clinico-pathological characteristics the only 
relevant data is that among BRCA1 mutation carriers a 
58% are triple negative (ER-, PR- and HER2-), as it has 
been also described by other groups. Analyzing the group 
of triple negative patients 70% has a mutation in BRCA1. 
The screening of 453 high risk breast cancer patients 
from different regions of Chile revealed the presence of 
nine founder mutations, 4 in BRCA1 and 5 in BRCA2. 
Figure 1: Geographical distribution of recurrent mutations. A map of the Chilean territory indicating cities where patients were 
recruited is shown. Each mutation is represented with specific color, and each carrier family is indicated by a colored circle.
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These mutations are shared by 2 to 10 unrelated families 
spread in different regions of Chile, and correspond to 
77.5% (55/71) of mutation carriers. All unrelated patients 
having the same mutation share a minimum haplotype 
revealing a common ancestor for each mutation. In several 
populations, as it is mentioned in the introduction, founder 
or recurrent mutations have been described; however the 
Chilean panel is until today the one containing the highest 
amount of founder mutations and also representing 
the highest percentage (77.5%) of BRCA1 and BRCA2 
mutation carriers, in a single population. These results 
reveal an excellent low cost panel to screen BRCA1 and 
BRCA2 carriers in Chile, among breast cancer patients 
including cases apparently sporadic.
Figure 2: Minimum common haplotypes identified for each recurrent mutation in BRCA1 (A) and BRCA2 (B). Values under each STR 
marker indicate the size of the shared alleles. Scheme (bottom image) represents the localization of all markers and mutations in relation 
to each gene.
Oncotarget74238www.impactjournals.com/oncotarget
It is important to highlight that the three Ashkenazi-
Jewish founder mutations are not frequently observed 
in our population as occurs in Argentina and Brazil. 
Considering the two large studies in Chile that include 
almost 800 patients [21] (and this study) three families 
carry the BRCA1 c.68_69delAG (formerly known as 
185delAG), two carry BRCA2 c.5946delT (also known as 
6174delT), and one present BRCA1 c.5266dupC (formerly 
known as 5382insC), representing less than 7% of Chilean 
mutation carriers, while in Argentina is close to 35% [24]. 
In the case of our group of families among 13 Ashkenazi 
Jewish only 2 present a mutation. Family with c.5266dupC 
is not from Ashkenazi Jewish origin. These results suggest 
that the Jewish community in Chile have a different ethnic 
origin compared to those in Brazil and Argentina, or that 
the prevalence of these mutations among the founders of 
this community in our country was lower than that in other 
countries from the region.
In Latin America, there are a few mutations with 
a demonstrated founder effect described in different 
Table 2: Novel variants in BRCA1 and BRCA2 in Chilean patients
Gene Exon/Intron
Hgvs 
Nomenclature Protein Effect
Number of Breast Cancer 
Patients
Co-ocurrence with 
BRCA Pathogenic 
Variant
In silico Analysis 
SYNONIMOUS VARIANTS
BRCA1 3 c.102T>G p.Pro34= 1/306 YES Null effect (a,b,g)
BRCA1 20 c.5211A>G p.Arg1737= 1/306 NO Null effect (a,b,g)
NON-SYNONIMOUS  
VARIANTS
BRCA1 11 c.1961A>C p.Lys654Thr 1/306 NO Damaging (d); Null effect (a,c,e,f)
BRCA1 16 c.4746C>G p.Asp1582Glu 1/306 NO Null effect (a,c,d,e,f)
BRCA2 11 c.2542A>C p.Lys848Gln 1/306 NO Damaging (e,f);Null effect (a,c,d)
STOP CODON  VARIANT
BRCA2 27 c.10225C>T p.Gln3409Ter 1/306 NO Damaging (a)
NON-CODING VARIANTS
BRCA1 I11 c.4097–164T>C NO 1/306 NO -
BRCA1 I20 c.5278–21C>T NO 2/306 NO -
BRCA2 I3 c.316+73A>G NO 1/306 NO -
BRCA2 I3 c.316+135G>A NO 1/306 NO -
BRCA2 I22 c.8954–74T>C NO 1/306 NO -
a) HCI, Breast Cancer Genes Prior Probabilities, b) VEP, Variant Effect Predictor, c) Align-GVGD, d) SIFT, e) PROVEAN, f) PolyPhen-2, g) HSF, Human 
Splice Finder.
Table 3: Distribution of BRCA1 and BRCA2 mutation carriers according to selection criteria
Patients classification Total Patients
With mutation Without mutation, n (%)
BRCA1, n (%) BRCA2, n (%)
With family history
Three or more relatives with breast 
cancer > 45 y 73 1 (1.4%) 5 (6.8%) 67 (91.8%)
Two relatives with breast cancer, 
one < 45 y 200 11 (5.5%) 19 (9.5%) 170 (85.0%)
Two or more relatives, one with 
ovarian cancer 53 12 (22.6%) 8 (15.1%) 33 (62.3%)
Two or more relatives, one male 
breast cancer 10 0 (0%) 4 (40%) 6 (60.0%)
Total 336 24 (7.1%) 36 (10.7%) 276 (82.2%)
No family history
Diagnosed < 40 y 84 6 (7.1%) 1 (1.2%) 77 (91.7%)
Bilateral breast cancer 27 2 (7.4%) 2 (7.4%) 23 (85.2%)
Breast and ovarian cancer 6 0 (0.0%) 0 (0.0%) 6 (100%)
Total 117 8 (6.8%) 3 (2.6%) 106 (90.6%))
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populations: Mexico (BRCA1 ex9–12del), Brazil (BRCA1 
5382insC), Colombia (BRCA1 3450del4, A1708E, and 
BRCA2 3034del4) and US Hispanics (BRCA1 185delAG, 
IVS5+1G>A, S955X, 2552delC and R1443X) [20, 25, 26]. 
Other recurrent mutations have been described in Latin 
American populations which founder effect has not yet 
been tested. The majority of mutations in BRCA1 or 
BRCA2 found in Latin-American breast cancer patients 
are private for each population, with very few mutations 
shared between countries [27]. Recently a panel of BRCA1 
and BRCA2, HISPANEL [28] has been constructed with 
diverse mutations from Hispanic breast cancer women 
from USA, based on the information in manuscripts 
describing mutations in BRCA1 and BRCA2 from Latin 
American countries and data bases. The HISPANEL, 
including close to 100 recurrent mutations, has been 
applied in breast cancer patients from Mexico, Colombia, 
Peru and Brazil, with diverse results [29–32], due to the 
diversity of BRCA1 and BRCA2 mutations among different 
Latin American populations, and the variable criteria to 
select the patients to be analyzed. Indeed our study as well 
as another study in Chilean patients [21], have shown that 
only 6 Chilean mutations are present in the HISPANEL, 
among which only three are Chilean founder mutations, 
representing only 25% of mutation carriers. This analysis 
confirms that the HISPANEL is not reliable for screening 
BRCA1/2 mutations in our breast cancer patients. In 
addition we found very few mutations shared with other 
Latin-American populations revealing that most mutations 
where introduced in the continent by independent events.
In relation to the 9 founder mutations described 
in this study c.1504_1507delTTAA and c.3817C>T in 
BRCA1 are not described elsewhere consisting in private 
mutations from Chile. In addition c.4740_4741dupTG 
in BRCA2 was also detected in two families from 
Argentina, and c.145G>T in BRCA2, was described in 
one Argentinian family. Due to the frequent migration 
events between these two countries this finding is not 
rare. It is noteworthy that mutation c.145G>T in BRCA2 
was detected exclusively in patients recruited at Valdivia 
(South of Chile), probably representing a specific 
settlement of colonists (Figure 1). In the contrary the other 
8 founder mutations are present in different cities along 
the Chilean territory (Figure 1). 
An interesting case is the mutation in BRCA1, 
c.3331_3334delCAAG, that is also founder in Colombia, 
Spain and Portugal (Tuazon A, manuscript in preparation), 
and also recurrent in 4 Brazilian families [33]. This 
mutation has been globally described among Caucasian 
population from Europe, Australia and America (BIC). 
In concordance with our history of colonization 
BRCA1 founder mutations c.3331_3334delCAAG and 
c.3759dupT, as well as BRCA2 founder mutations 
c.145G>T and c.5146_5149delTATG have been described 
in Spain. This latter mutation, c.5146_5149delTATG in 
BRCA2, was first reported in families from the regions 
of Castilla-León [34] and Aragon [35] in Spain and later 
stablished as a Spanish founder mutation [36] originated 
at Castilla-León. 
The finding of 9 founder mutations among Chilean 
breast cancer families is a consequence of history of 
colonization, and how the population of Chile was settled. 
Several historical records mention that the indigenous 
population in Chile at the time of the arrival of Spaniards 
in 1541 was around 1 million, but it was dramatically 
reduced as a consequence of battles with Conquerors, 
dying mainly male indigenous, as well as diseases 
(Instituto Nacional de Estadísticas, INE 2009). In addition 
mostly male Spaniards came to Chile during the first three 
centuries, with a very scarce population increase; therefore 
the genetic bases of the Chilean population come from 
mating between Amerindian women and Spanish men [37] 
(and INE, 2009). These historic issues have been revealed 
in a previous study from our group, demonstrating that the 
Chilean population is composed in 84% by Amerindian 
mitochondrial DNA (maternal lineage) and 32% of 
Amerindian Y chromosome (paternal lineage) [38]. Even 
though at the end of the XIX century considerable German 
and French migrations occurred, and others thereafter, 
the genetic composition of the Chilean population today 
still reflects the history of the first three centuries [39]. 
We could suggest that the dramatic reduction of the 
Amerindian population in conjunction with the arrival of 
Spanish conquerors (highly predominant in males), for 
close to 300 years, was a favorable scenario to establish 
founder genetic markers in the population. In addition 
the geographic position of Chile is also beneficial to 
establish founder genetic markers or mutations since no 
immigrations came from the Pacific Ocean, few from 
the north of Chile and very scarce from Europe through 
Argentina.
MATERIALS AND METHODS
Patients 
A total of 336 patients with familial breast/ovarian 
cancer were recruited from 1999 to 2015 using either of 
the following family history criteria: 1) three or more 
relatives with breast cancer diagnosed after 45 years 
old, 2) two relatives with breast cancer at least one 
diagnosed before age 45, 3) one breast cancer and one 
ovarian cancer at any age, or 4) one male breast cancer 
and one female breast cancer. The 117 patients with 
breast cancer and no family history were selected by 5) 
being diagnosed at 40 years old or younger, 6) presenting 
bilateral breast cancer or 7) presenting breast and ovarian 
cancer.  The selected patients were recruited from three 
Public Hospitals (Antofagasta, Valdivia and Santiago) 
and one private Institution (Santiago). Two of the public 
Hospitals assist patients from Regions XV, I, II, and III 
(Antofagasta Hospital, North of Chile) and IX, XIV, 
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X and XI (Valdivia Hospital, South of Chile), covering 
4.5 million Chilean inhabitants (28% of total Chile. Based 
on Cense 2012). The third Public Hospital (Santiago) 
assists close to 25% of total patients from the Metropolitan 
Region. Low and middle income patients attend to these 
three hospitals.
After informed consent, blood samples were 
obtained from affected individuals and relatives. This 
protocol, which adheres to the Helsinki declaration and 
local regulations, was approved by the Ethics Committees 
belonging to all the Hospitals where the patients came 
from. All patients received genetic counselling before and 
after the genetic test.
Mutation screening
DNA was isolated using the method described by 
Lahiri and Nurnberger [39]. PCR amplification covering 
all coding sequences and intron-exon boundaries, of exons 
2 to 24 (BRCA1) and 2 to 27 (BRCA2) was performed by 
standard methods. In the first 147 patients, BRCA1 and 
BRCA2 mutations were screened through heteroduplex 
analysis, Protein Truncation Test (PTT) Single Strand 
Conformational Polymorphism (SSCP), and Sanger 
sequencing of selected exons. In 306 patients mutation 
screening was performed by next-generation sequencing 
(NGS). Enrichment of BRCA1 and BRCA2 sequences 
for NGS was performed with BRCA MASTR v2.1 
(Multiplicom, Belgium) as follows. Briefly, 5 multiplex 
reactions were used to amplify all coding exons and intron/
exon boundaries of BRCA1 and BRCA2 (93 amplicons), 
followed by sample barcoding. Sequencing was performed 
in a Junior Roche 454. Analysis of sequencing data was 
performed with Amplicon Variant Analyzer (AVA) 
software (Roche) using references sequences for BRCA1 
and BRCA2 provided by Multiplicom, and filtered to allow 
the call of all possible variants. The obtained variants were 
filtered manually using a 30× depth cutoff for each forward 
and reverse sequences, and allelic variant frequencies over 
30%. Allelic frequencies for heterozygous variants were 
determined between 30 and 70%, and for homozygous 
variants over 70%. All detected variants were confirmed 
by Sanger sequencing, and named according to the 
Human Genome Variation Society (http://www.hgvs.org/
mutnomen/) and relative to GenBank reference sequences 
(BRCA1: L78833 and BRCA2: AY436640). In addition, all 
new mutations identified in the 306 patients analyzed by 
NGS were re-screened in the first group of patients. 
Clinical significance determination for sequence 
variants
Novel variants were defined as pathogenic (class 5), 
likely pathogenic (class 4), uncertain significance 
(VUS; class 3), likely not pathogenic (class 2) and not 
pathogenic (class 1) following recommendations of the 
American College of Medical Genetics and Genomics 
[40] and ENIGMA (ENIGMA consortium, https://
enigmaconsortium.org/library/general-documents). The 
already described variants (pathogenic, non-pathogenic 
and uncertain) were assigned after reviewing information 
available in BIC (Breast Cancer Information Core, https://
research.nhgri.nih.gov/projects/bic/), ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar/), BRCA Share (former 
Universal Mutation Database, http://umd.be/) 1000 
genomes (http://www.internationalgenome.org/), Leiden 
Open Variation Database (http://www.lovd.nl/3.0/home) 
and published manuscripts. Novel variants not classified 
under pathogenic, were analyzed with two integrative 
platforms a) HCI Breast Cancer Genes Prior Probabilities 
(http://priors.hci.utah.edu/PRIORS/references.php); b) 
Variant Effect Predictor [41] (VEP, http://www.ensembl.
org/info/docs/tools/vep/index.html); and the recommended 
in silico tools [40] (ACMG and ENIGMA), c) Align-
GVGD [42] (http://agvgd.hci.utah.edu), d) SIFT [43] 
(http://sift.jcvi.org), e) PROVEAN [44] (http://provean.
jcvi.org/index.php), f) PolyPhen-2 [45] (http://genetics.
bwh.harvard.edu/pph2). In addition, synonymous variants 
were also assessed for splicing effect using Human Splice 
Finder [46] (HSP, http://www.umd.be/HSF3/). Default 
parameters were applied for each tool. 
Founder haplotype determination for recurrent 
mutations
We analyzed a total of 11 Short Tandem Repeats (STR) 
markers. For mutations in BRCA1: D17S1323, D17S1322, 
D17S855, D17S1320, D17S1326 and D17S1327, covering 
0.68 Mb, and for mutations in BRCA2: D13S260, D13S1698, 
D13S267, D13S171 and D13S310 covering 1.82 Mb. All 
loci were amplified by PCR using primers, end-labeled 
with different fluorophores (VIC, 6-FAM, PET and NED). 
PCR products were analyzed by capillary electrophoresis 
in an ABI PRISM 3130x fragment analyzer (Applied 
Technologies) using Peak Scanner Software 2 to confirm 
product amplification and size. The STR alleles associated 
to each recurrent mutation were grouped in haplotypes for 
all samples carrying the same mutation, and phases were 
confirmed by PHASE v2.1 [47, 48] (stephenslab.ucicago.
edu/phase). A minimum common haplotype was determined 
to define a common ancestor.
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